1. Home
  2. LPTX vs TOUR Comparison

LPTX vs TOUR Comparison

Compare LPTX & TOUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • TOUR
  • Stock Information
  • Founded
  • LPTX 2011
  • TOUR 2006
  • Country
  • LPTX United States
  • TOUR China
  • Employees
  • LPTX N/A
  • TOUR N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • TOUR Transportation Services
  • Sector
  • LPTX Health Care
  • TOUR Consumer Discretionary
  • Exchange
  • LPTX Nasdaq
  • TOUR Nasdaq
  • Market Cap
  • LPTX 119.6M
  • TOUR 135.4M
  • IPO Year
  • LPTX N/A
  • TOUR 2014
  • Fundamental
  • Price
  • LPTX $0.39
  • TOUR $1.09
  • Analyst Decision
  • LPTX Buy
  • TOUR
  • Analyst Count
  • LPTX 3
  • TOUR 0
  • Target Price
  • LPTX $8.50
  • TOUR N/A
  • AVG Volume (30 Days)
  • LPTX 321.2K
  • TOUR 257.9K
  • Earning Date
  • LPTX 05-12-2025
  • TOUR 03-14-2025
  • Dividend Yield
  • LPTX N/A
  • TOUR N/A
  • EPS Growth
  • LPTX N/A
  • TOUR N/A
  • EPS
  • LPTX N/A
  • TOUR N/A
  • Revenue
  • LPTX N/A
  • TOUR $72,825,718.00
  • Revenue This Year
  • LPTX N/A
  • TOUR $20.26
  • Revenue Next Year
  • LPTX N/A
  • TOUR $15.73
  • P/E Ratio
  • LPTX N/A
  • TOUR N/A
  • Revenue Growth
  • LPTX N/A
  • TOUR 38.57
  • 52 Week Low
  • LPTX $0.39
  • TOUR $0.59
  • 52 Week High
  • LPTX $4.79
  • TOUR $1.76
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 18.56
  • TOUR 56.83
  • Support Level
  • LPTX $0.40
  • TOUR $1.03
  • Resistance Level
  • LPTX $0.46
  • TOUR $1.14
  • Average True Range (ATR)
  • LPTX 0.03
  • TOUR 0.05
  • MACD
  • LPTX 0.06
  • TOUR 0.01
  • Stochastic Oscillator
  • LPTX 0.00
  • TOUR 52.94

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About TOUR Tuniu Corporation

Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. All the company's revenues are derived from within the People's Republic of China.

Share on Social Networks: